FTC Clears Kirin’s Acquisition Of Kyowa Hakko
This article was originally published in PharmAsia News
Executive Summary
The U.S. Federal Trade Commission March 25 approved Japanese brewer Kirin Holdings' acquisition of pharmaceutical company Kyowa Hakko Kogyo Co. The FTC announced that it had reviewed the case and found no concerns regarding competition. Kirin Holding has been buying Kyowa's stock, and plans to increase its holdings to 50.1 percent by April 1. Kirin Pharmaceutical Co., the pharmaceutical business division of Kirin Holdings, is scheduled to merge with Kyowa Hakko on Oct. 1. (Click here for more-Japanese language
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.